

II. REMARKS

The remarks that follow are supplemental to the remarks in the response filed on May 24, 2004, in reply to the official action dated December 22, 2003.

Preliminary Remarks

Claim 61 is amended as follows:

- (a) The preamble of claim 61 is amended to state that the claim is directed to: “[a] method for producing an antibody heterodimer comprising an anti-CD20 antibody and an anti-CD23 antibody”.
- (b) The following phrase is deleted from lines 5-6 of claim 61:
“wherein the location of said cysteine does not interfere with the antigen binding properties of said antibody dimer”
- (c) The last line of claim 61 is amended to read as follows:
“wherein following dimerization, the anti-CD20 antibody has binding specificity to CD20 and the anti-CD23 antibody has binding specificity to CD23.”

The preamble of claim 61 is amended to more clearly identify the subject matter that is claimed. The phrase in lines 5-6 of claim 61 is deleted and the phrase in the last line is amended to give conformity with the language of the written description.

All rejections having been addressed, it is respectfully submitted that the present application is in condition for allowance and a Notice to that effect is earnestly solicited. If any points remain in issue, which the examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By 

Thomas A. Cawley, Jr., Ph.D.
Reg. No. 40,944
Tel.: (703) 905-2144
Fax.: (703) 905-2500

PILLSBURY WINTHROP LLP
P.O. Box 10500
McLean, VA 22102